CL2019000728A1 - Formas cristalinas. - Google Patents

Formas cristalinas.

Info

Publication number
CL2019000728A1
CL2019000728A1 CL2019000728A CL2019000728A CL2019000728A1 CL 2019000728 A1 CL2019000728 A1 CL 2019000728A1 CL 2019000728 A CL2019000728 A CL 2019000728A CL 2019000728 A CL2019000728 A CL 2019000728A CL 2019000728 A1 CL2019000728 A1 CL 2019000728A1
Authority
CL
Chile
Prior art keywords
crystalline forms
pharmaceutical compositions
forms
crystal
phosphonopropionil
Prior art date
Application number
CL2019000728A
Other languages
English (en)
Inventor
Raumer Markus Von
Daniel Leuenberger
Stefan Reber
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019000728A1 publication Critical patent/CL2019000728A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCIÓN SE RELACIONA A FORMAS CRISTALINAS DE CLORHIDRATO DE ÉSTER BUTÍLICO DEL ÁCIDO 4-((R)-2- {[6-((S)-3-METOXI-PIRROLIDINA-1-IL)-2-FENIL-PIRIMIDINA-4-CARBONIL]-AMINO}-3-FOSFONOPROPIONIL)-PIPERAZIN-1- CARBOXÍLICO, PROCESOS PARA LA PREPARACIÓN DE LAS MISMAS, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LAS FORMAS CRISTALINAS, COMPOSICIONES FARMACÉUTICAS PREPARADAS DE LAS FORMAS CRISTALINAS Y SUS USOS COMO UN MEDICAMENTO, ESPECIALMENTE COMO UN ANTAGONISTA DEL RECEPTOR P2Y12.
CL2019000728A 2016-09-22 2019-03-21 Formas cristalinas. CL2019000728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22

Publications (1)

Publication Number Publication Date
CL2019000728A1 true CL2019000728A1 (es) 2019-07-05

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000728A CL2019000728A1 (es) 2016-09-22 2019-03-21 Formas cristalinas.

Country Status (28)

Country Link
US (3) US10730896B2 (es)
EP (2) EP3515924B1 (es)
JP (1) JP7097369B2 (es)
KR (1) KR102552795B1 (es)
CN (1) CN109715639B (es)
AU (1) AU2017331930B2 (es)
BR (1) BR112019004845A2 (es)
CA (1) CA3037794A1 (es)
CL (1) CL2019000728A1 (es)
CY (1) CY1125052T1 (es)
DK (1) DK3515924T3 (es)
EA (1) EA201990723A1 (es)
ES (1) ES2908572T3 (es)
HR (1) HRP20220234T1 (es)
HU (1) HUE057772T2 (es)
IL (1) IL265445B2 (es)
LT (1) LT3515924T (es)
MA (1) MA46266B1 (es)
MX (1) MX2019003093A (es)
MY (1) MY193080A (es)
PH (1) PH12019500567A1 (es)
PL (1) PL3515924T3 (es)
PT (1) PT3515924T (es)
RS (1) RS62946B1 (es)
SI (1) SI3515924T1 (es)
TW (1) TWI752086B (es)
UA (1) UA124073C2 (es)
WO (1) WO2018055016A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009559A (es) 2017-03-15 2019-10-15 Idorsia Pharmaceuticals Ltd Administracion subcutanea de un antagonista del receptor p2y12.
KR20230041732A (ko) 2020-07-15 2023-03-24 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물
JP2024524658A (ja) 2021-07-13 2024-07-05 イドルシア・ファーマシューティカルズ・リミテッド 4-((r)-2-{[6-((s)-3-メトキシ-ピロリジン-1-イル)-2-フェニル-ピリミジン-4-カルボニル]-アミノ}-3-ホスホノ-プロピオニル)-ピペラジン-1-カルボン酸ブチルエステルの合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
KR20050085580A (ko) 2002-12-11 2005-08-29 쉐링 악티엔게젤샤프트 혈소판 아데노신 디포스페이트 수용체 길항제로서의2-아미노카르보닐-퀴놀린 화합물
CN1863810B (zh) 2003-04-09 2010-12-01 惠氏公司 [2-(8,9-二氧代-2,6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
CA2623213C (en) 2005-10-21 2014-01-14 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MY153427A (en) 2007-04-23 2015-02-13 Sanofi Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CN102405220B (zh) 2009-04-22 2015-05-27 埃科特莱茵药品有限公司 噻唑衍生物及其作为p2y12受体拮抗剂的用途
MX2019009559A (es) 2017-03-15 2019-10-15 Idorsia Pharmaceuticals Ltd Administracion subcutanea de un antagonista del receptor p2y12.

Also Published As

Publication number Publication date
KR102552795B1 (ko) 2023-07-06
IL265445B2 (en) 2024-05-01
BR112019004845A2 (pt) 2019-06-04
TW201813965A (zh) 2018-04-16
UA124073C2 (uk) 2021-07-14
AU2017331930B2 (en) 2021-07-15
WO2018055016A1 (en) 2018-03-29
CN109715639A (zh) 2019-05-03
KR20190052704A (ko) 2019-05-16
IL265445A (en) 2019-05-30
US20200017534A1 (en) 2020-01-16
MY193080A (en) 2022-09-26
US20210009614A1 (en) 2021-01-14
CA3037794A1 (en) 2018-03-29
CY1125052T1 (el) 2024-02-16
PT3515924T (pt) 2022-03-11
ES2908572T3 (es) 2022-05-03
DK3515924T3 (da) 2022-03-21
EP3515924B1 (en) 2021-12-15
EA201990723A1 (ru) 2019-10-31
EP3981774A1 (en) 2022-04-13
CN109715639B (zh) 2022-04-19
HUE057772T2 (hu) 2022-06-28
US11365209B2 (en) 2022-06-21
PH12019500567A1 (en) 2019-11-18
MA46266A (fr) 2019-07-31
IL265445B1 (en) 2024-01-01
MA46266B1 (fr) 2022-02-28
RS62946B1 (sr) 2022-03-31
EP3515924A1 (en) 2019-07-31
AU2017331930A1 (en) 2019-03-07
JP7097369B2 (ja) 2022-07-07
TWI752086B (zh) 2022-01-11
LT3515924T (lt) 2022-03-10
PL3515924T3 (pl) 2022-04-11
JP2019529553A (ja) 2019-10-17
SI3515924T1 (sl) 2022-04-29
NZ750772A (en) 2023-10-27
US20220275011A1 (en) 2022-09-01
MX2019003093A (es) 2019-07-18
HRP20220234T1 (hr) 2022-05-13
US10730896B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
SV2017005555A (es) Composiciones de acido obeticolico y metodos de uso
CO2018004124A2 (es) Compuestos heterocíclicos
CL2017000786A1 (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
ECSP19012917A (es) Compuestos de pirrolizina sustituida y usos de los mismos
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
PH12017501191A1 (en) Quinazoline derivatives used to treat hiv
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
SV2018005776A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida
CO2019006673A2 (es) Polimorfos
CO2019006687A2 (es) Polimorfos
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
CL2019000728A1 (es) Formas cristalinas.
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2017000540A1 (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida.
UY36864A (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CO2018002364A2 (es) Una novedosa forma de isoxadifeno-etilo, un proceso para su preparación y uso de la misma